Invivyd gains FDA fast track for next-generation COVID-19 antibody
Invivyd (NASDAQ:IVVD) received U.S. Food and Drug Administration Fast Track designation for VYD2311, an investigational monoclonal antibody designed as a long-acting, intramuscular alternative to traditional vaccines for individuals at high risk of severe COVID-19.















-640x358.jpg&w=3840&q=75)




-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)